“This research is taking promising steps towards a new one-of-a-kind therapy which targets tau, a damaging protein in the brains of people living with Alzheimer’s, preventing it from clumping together,” said Richard Oakley, associate director of research and innovation at the Alzheimer’s Society UK, which funded the research.

Researchers have hailed a breakthrough in the development of drugs to treat Alzheimer’s.Scientists have created a drug that works by targeting both key areas of a protein linked to the disease.The study found that the medication,

An international team of researchers have made a promising breakthrough in the development of drugs to treat Alzheimer’s Disease. For the first time, scientists have developed a drug that works on both major aggregation-promoting ‘hotspots’ of the Tau protein in the brain - a key driver of neurodegeneration.

Researchers from a study funded by the Alzheimer’s Society of UK have developed a new drug known as RI-AG03 that they say can prevent the build-up of toxic proteins in the brain that lead to neurodegenerative issues causing Alzheimer’s disease.

Developed by international researchers led by British experts, RI-AG03, tackles two 'hotspots' on the protein that leads to the memory robbing condition getting worse.

New study is a promising ‘first’ in Alzheimer’s drug development - Researchers believe their work will have a significant impact on drug discovery efforts in the field of neurodegenerative diseases.